Storia in 16 fonti

How a pharma megamerger could squelch R&D

Combining two drug giants with overlapping portfolios could put cost efficiencies ahead of innovation.

Raccontata da

cityam.com+4 altre

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

axios.comStai leggendo2 h fa

How a pharma megamerger could squelch R&D

Combining two drug giants with overlapping portfolios could put cost efficiencies ahead of innovation.

originale

zerohedge.com

Timeline cronologica

domenica 2 agosto 2026·handelsblatt.com
Pharma: AstraZeneca erwägt Mega-Fusion mit US-Rivalen Bristol Myers Squibb
Es wäre eine der größten Fusionen in der Wirtschaftsgeschichte. Laut einem Medienbericht wurden entsprechende Gespräche geführt. Ob es zu einem Zusammenschluss kommt ist jedoch…
domenica 2 agosto 2026·valor.globo.com
AstraZeneca explora possível fusão com a Bristol Myers Squibb, diz jornal
União poderia criar gigante farmacêutica de US$ 400 bilhões em valor de mercado

How a pharma megamerger could squelch R&D

Confronto fonti

How a pharma megamerger could squelch R&D

Timeline cronologica

Pharma: AstraZeneca erwägt Mega-Fusion mit US-Rivalen Bristol Myers Squibb

AstraZeneca explora possível fusão com a Bristol Myers Squibb, diz jornal

$400 Billion Pharma Megadeal? Jefferies Calls Potential AstraZeneca-Bristol Myers Merger A "Head Scratcher"

An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.

Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea

An AstraZeneca, Bristol Myers Squibb merger could create a cancer-drug giant, but analysts call it 'odd'

AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports

AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports

Pharma giants AstraZeneca, Bristol Myers Squibb in talks on $512 billion megadeal: Report

AstraZeneca, Bristol Myers Squibb Reportedly in Talks for $400 Billion Merger - AstraZeneca (NYSE:AZN)

AstraZeneca, Bristol Myers are in talks about merger — report

AstraZeneca said to have explored Bristol Myers merger | Fortune

An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.

Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea

Pharma: Astra-Zeneca erwägt wohl Mega-Fusion mit Bristol-Myers Squibb

AstraZeneca: Pharmakonzern prüft 400-Milliarden-Dollar-Fusion mit Bristol Myers

AstraZeneca Held Talks to Combine With Bristol Myers Squibb, FT Says, Citing Sources

Astrazeneca explores $400bn megadeal with US rival

AstraZeneca in talks over £300bn mega-merger with US rival – reports

AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb

AstraZeneca, BMS discuss $400B pharma mega-deal

AstraZeneca ‘in talks to create £300bn pharmaceutical giant’

Ft: «AstraZeneca tratta con Bristol Myers Squibb per una maxi fusione da 400 miliardi» - Lettera43

Pharma: Mega-Fusion zwischen Astra Zeneca und Bristol Myers im Gespräch

Insider: Mega-Fusion zwischen Astra Zeneca und Bristol Myers im Gespräch